Efinopegdutide: Trials and FDA Status
Efinopegdutide is a glp-1/glucagon dual agonist (mash). This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- Investigational
- Phase
- Phase 2
- Sponsor
- Merck Sharp & Dohme
- Expected FDA decision
- None announced
- no primary source states a date (checked 2 Oct 2026)
- Trial IDs (NCT)
- NCT04944992, NCT05877547
Reported results
- 2023Phase 2a vs semaglutide in NAFLD (J Hepatol 2023): liver fat reduction at week 24“The least squares (LS) mean relative reduction from baseline in LFC at Week 24 was significantly (p <0.001) greater with efinopegdutide (72.7% [90% CI 66.8-78.7]) than with semaglutide (42.3% [90% CI 36.5-48.1])”pubmed.ncbi.nlm.nih.gov
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
- NCT05877547 (A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013); Phase 2): primary completion
- NCT05877547 (A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013); Phase 2): study start
- NCT05877547 (A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013); Phase 2): first posted on ClinicalTrials.gov
- Published in Journal of hepatology (2023): A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
- NCT04944992 (A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001); Phase 2): primary completion
- NCT04944992 (A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001); Phase 2): study start
- NCT04944992 (A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001); Phase 2): first posted on ClinicalTrials.gov
What the efinopegdutide registry entries specify
NCT04944992 is a phase 2a, randomised, open-label study comparing efinopegdutide (MK-6024) with an active comparator in people with nonalcoholic fatty liver disease.[1]
It enrolled 145 participants.[1]
It is completed: it started 2021-08-04 and reached primary completion on 2022-10-19.[1]
The phase 2b study (NCT05877547) is double-blind and placebo-controlled, in adults with precirrhotic nonalcoholic steatohepatitis.[2]
It enrolled 381 participants.[2]
It is also completed: it started 2023-06-23 and reached primary completion on 2025-12-29.[2]
One efinopegdutide arm in the phase 2b study escalates once weekly from 2 mg for 4 weeks to 4 mg for 48 weeks.[2]
Primary endpoints and trial length
The phase 2a primary outcome is the mean relative reduction in liver fat content, measured by MRI-PDFF after 24 weeks.[1]
The phase 2b primary outcome is the percentage of participants with NASH resolution without worsening of fibrosis at Week 52.[2]
From start to primary completion, the phase 2a spans 63 weeks and the phase 2b 131 weeks.
Calculated from NCT04944992 start 2021-08-04, primary completion 2022-10-19, type ACTUAL; NCT05877547 start 2023-06-23, primary completion 2025-12-29, type ACTUAL. Formula: weeks = round((primary completion date - start date) / 7 days)
Published result
In the phase 2a trial, liver fat fell by 72.7% with efinopegdutide against 42.3% with semaglutide at week 24.[3]
Sources
- 1A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) (NCT04944992)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 2A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) (NCT05877547)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 3A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.Journal of hepatology · 2023PMID 37355043Accessed 2 Oct 2026
Found an error? Report a correction.